LifeMine Therapeutics

LifeMine Therapeutics is a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™, a bold new approach that leverages evolutionary insights from fungi to unearth next-generation precision medicines. Founded in 2016, LifeMine is the first biotechnology company exploiting the unique ability of fungi to produce powerful drugs optimized through billions of years of evolution. Its data-immersive platform integrates human genetics and genomics, bioinformatics, machine learning, and synthetic biology to deeply mine fungal genomes for genetically encoded small molecules (GEMs). The company's lead program, LIFE-001, is advancing for the treatment of multiple immune-mediated disorders and organ transplant rejection. LifeMine's distinguished team includes co-founders Dr. Gregory Verdine (President & CEO), WeiQing Zhou (COO), and Dr. Richard Klausner (Chairman), with backing from GV and other leading life sciences investors.